Taysha Gene Therapies (TSHA) Current Leases (2022 - 2026)

Taysha Gene Therapies has disclosed Current Leases across 5 years of filings, most recently posting $1.8 million for Q1 2026.

• Current Leases for Q1 2026 came in at $1.8 million, up 0.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (up 0.88% YoY), and the FY2025 annual result was $1.9 million, down 0.64% from the prior year.
• Current Leases came in at $1.8 million for Q1 2026 at Taysha Gene Therapies, down from $1.9 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.9 million in Q4 2024 to a low of $1.5 million in Q4 2022.
• The 5-year median for Current Leases is $1.7 million (2023), against an average of $1.7 million.
• Across the five-year window, Current Leases climbed 18.01% in 2024 and retreated 8.1% in 2025, its largest moves.
• Taysha Gene Therapies' Current Leases stood at $1.5 million in 2022, then advanced by 8.22% to $1.6 million in 2023, then increased by 14.03% to $1.9 million in 2024, then decreased by 0.64% to $1.9 million in 2025, then slipped by 2.2% to $1.8 million in 2026.
• The last three Current Leases figures came in at $1.8 million (Q1 2026), $1.9 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.